2019 Future of Nasal Polyps R&D Pipeline Drugs and Companies- Analysis of Global Nasal Polyps Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments
The global demand for Nasal Polyps treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Nasal Polyps pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Nasal Polyps pipeline companies from advancing their products into Phase 3 or Phase 4.
Nasal Polyps Report Description
The H1 2019 pipeline review report on Nasal Polyps pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Nasal Polyps pipeline compounds.
The Nasal Polyps pipeline guide presents information on all active drugs currently being developed for Nasal Polyps. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Nasal Polyps pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Nasal Polyps drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Nasal Polyps product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Nasal Polyps pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Nasal Polyps pipeline report includes
REASONS TO BUY
Nasal Polyps Report Description
The H1 2019 pipeline review report on Nasal Polyps pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Nasal Polyps pipeline compounds.
The Nasal Polyps pipeline guide presents information on all active drugs currently being developed for Nasal Polyps. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Nasal Polyps pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Nasal Polyps drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Nasal Polyps product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Nasal Polyps pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Nasal Polyps pipeline report includes
- An overview of Nasal Polyps disease including symptoms, causes, diagnosis and available treatment options is provided.
- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
- Phase wise count of pipeline compounds
- Company wise list of pipeline compounds
- Mechanism of Action wise pipeline compounds
- For each pipeline product, the following details are provided-
- Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
- Current status of development
- Drug overview
- Mechanism of Action
- Pre-clinical and Clinical Trials
REASONS TO BUY
- The report is designed to help industry executives promote the success and continued growth of their organizations
- Get clear understanding of the entire Nasal Polyps pipeline, with details on active projects
- Stay ahead of the competition through comprehensive knowledge of Nasal Polyps pipeline progress
- Get in detail information of each product with updated information on each project along with key milestones
- Gain clear insights into the market through in-depth strategic analysis review
- Know the list of companies participating in global Nasal Polyps pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. GLOBAL NASAL POLYPS PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology
3. EXECUTIVE SUMMARY
3.1 Nasal Polyps Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Nasal Polyps pipeline, H1- 2019
3.5 Mechanism of Action wise Nasal Polyps Pipeline Candidates
4. GLAXOSMITHKLINE PLC NASAL POLYPS PIPELINE DETAILS
4.1 GlaxoSmithKline Plc Business Profile
4.2 GlaxoSmithKline Plc Nasal Polyps Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5. IDORSIA PHARMACEUTICAL LTD NASAL POLYPS PIPELINE DETAILS
5.1 Idorsia Pharmaceutical Ltd Business Profile
5.2 Idorsia Pharmaceutical Ltd Nasal Polyps Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6. KYOWA HAKKO KIRIN CO LTD NASAL POLYPS PIPELINE DETAILS
6.1 Kyowa Hakko Kirin Co Ltd Business Profile
6.2 Kyowa Hakko Kirin Co Ltd Nasal Polyps Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7. PFIZER INC NASAL POLYPS PIPELINE DETAILS
7.1 Pfizer Inc Business Profile
7.2 Pfizer Inc Nasal Polyps Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8. REGENERON PHARMACEUTICALS INC NASAL POLYPS PIPELINE DETAILS
8.1 Regeneron Pharmaceuticals Inc Business Profile
8.2 Regeneron Pharmaceuticals Inc Nasal Polyps Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9. ROCHE NASAL POLYPS PIPELINE DETAILS
9.1 Roche Business Profile
9.2 Roche Nasal Polyps Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10. SUZHOU CONNECT BIOPHARMACEUTICALS LTD NASAL POLYPS PIPELINE DETAILS
10.1 Suzhou Connect Biopharmaceuticals Ltd Business Profile
10.2 Suzhou Connect Biopharmaceuticals Ltd Nasal Polyps Drug Details
10.2.1 Drug Snapshot
10.2.1.1 Originator
10.2.1.2 Collaborator/Co-Developer
10.2.1.3 Route of Administration
10.2.1.4 Orphan Drug/Fast Track/Special Designation
10.2.1.5 Area
10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11. LATEST NASAL POLYPS DRUG PIPELINE DEVELOPMENTS, 2019
12. APPENDIX
12.1 About Us
12.2 Sources and Methodology
12.3 Contact Information
1.1 List of Tables
1.2 List of Figures
2. GLOBAL NASAL POLYPS PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology
3. EXECUTIVE SUMMARY
3.1 Nasal Polyps Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Nasal Polyps pipeline, H1- 2019
3.5 Mechanism of Action wise Nasal Polyps Pipeline Candidates
4. GLAXOSMITHKLINE PLC NASAL POLYPS PIPELINE DETAILS
4.1 GlaxoSmithKline Plc Business Profile
4.2 GlaxoSmithKline Plc Nasal Polyps Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5. IDORSIA PHARMACEUTICAL LTD NASAL POLYPS PIPELINE DETAILS
5.1 Idorsia Pharmaceutical Ltd Business Profile
5.2 Idorsia Pharmaceutical Ltd Nasal Polyps Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6. KYOWA HAKKO KIRIN CO LTD NASAL POLYPS PIPELINE DETAILS
6.1 Kyowa Hakko Kirin Co Ltd Business Profile
6.2 Kyowa Hakko Kirin Co Ltd Nasal Polyps Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7. PFIZER INC NASAL POLYPS PIPELINE DETAILS
7.1 Pfizer Inc Business Profile
7.2 Pfizer Inc Nasal Polyps Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8. REGENERON PHARMACEUTICALS INC NASAL POLYPS PIPELINE DETAILS
8.1 Regeneron Pharmaceuticals Inc Business Profile
8.2 Regeneron Pharmaceuticals Inc Nasal Polyps Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9. ROCHE NASAL POLYPS PIPELINE DETAILS
9.1 Roche Business Profile
9.2 Roche Nasal Polyps Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10. SUZHOU CONNECT BIOPHARMACEUTICALS LTD NASAL POLYPS PIPELINE DETAILS
10.1 Suzhou Connect Biopharmaceuticals Ltd Business Profile
10.2 Suzhou Connect Biopharmaceuticals Ltd Nasal Polyps Drug Details
10.2.1 Drug Snapshot
10.2.1.1 Originator
10.2.1.2 Collaborator/Co-Developer
10.2.1.3 Route of Administration
10.2.1.4 Orphan Drug/Fast Track/Special Designation
10.2.1.5 Area
10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11. LATEST NASAL POLYPS DRUG PIPELINE DEVELOPMENTS, 2019
12. APPENDIX
12.1 About Us
12.2 Sources and Methodology
12.3 Contact Information
